验证数据展示
经过测试的应用
Positive IF-P detected in | mouse brain tissue |
Positive IF/ICC detected in | SH-SY5Y cells |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
CL488-66140 targets C9orf72 in IF/ICC, IF-P applications and shows reactivity with human, mouse, rat samples.
经测试应用 | IF/ICC, IF-P Application Description |
经测试反应性 | human, mouse, rat |
免疫原 | C9orf72 fusion protein Ag21080 种属同源性预测 |
宿主/亚型 | Mouse / IgG2a |
抗体类别 | Monoclonal |
产品类型 | Antibody |
全称 | chromosome 9 open reading frame 72 |
别名 | Guanine nucleotide exchange factor C9orf72, DENNL72, DENND9, C9RANT, 3D2H6 |
计算分子量 | 481 aa, 54 kDa |
观测分子量 | 55 kDa |
GenBank蛋白编号 | BC020851 |
基因名称 | C9orf72 |
Gene ID (NCBI) | 203228 |
RRID | AB_2883271 |
偶联类型 | CoraLite® Plus 488 Fluorescent Dye |
最大激发/发射波长 | 493 nm / 522 nm |
形式 | Liquid |
纯化方式 | Protein A purification |
UNIPROT ID | Q96LT7 |
储存缓冲液 | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3 |
储存条件 | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
C9ORF72 has a domain whith polymorphic hexanucleotide repeat (GGGGCC). The C9ORF72-hexanucleotide repeat expansions have been recently identified as genetic markers in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). FTLD-TDP has five subtypes: Sporadic FTLD, GRN mutation FTLD, TARDBP mutation FTLD, VCP mutation FTLD and C9ORF72 mutation FTLD. The C9ORF72 repeat expansions may indicate a worse prognosis in ALS. Human C9ORF72 has some isoforms with MW 54-60 kDa and 25-30 kDa. Mouse C9orf72 has some isoforms with MW 50-60 kDa and 35 kDa.
实验方案
Product Specific Protocols | |
---|---|
IF protocol for CL Plus 488 C9orf72 antibody CL488-66140 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |